{"id":"sl-fentanyl","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=SL fentanyl","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T04:04:09.005221+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:04:14.550230+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SL fentanyl","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:04:14.757342+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Mu opioid receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:04:16.369353+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201159/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:04:16.036373+00:00"}},"_dailymed":null,"_scrapedAt":"2026-03-27T23:37:53.319Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T04:04:17.657872+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT04263909","phase":"PHASE4","title":"The Impact of Sublingual Sufentanil on Postoperative Pain and Analgesic Requirements in Spine Surgery Patients","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-12-01","conditions":"Spine Fusion, Pain, Postoperative, Opioid Use","enrollment":199},{"nctId":"NCT05053308","phase":"NA","title":"Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement","status":"WITHDRAWN","sponsor":"Seoul National University","startDate":"2022-12-01","conditions":"Cancer Pain, Breakthrough Pain","enrollment":""},{"nctId":"NCT02514252","phase":"PHASE2","title":"Sublingual Fentanyl for the Management of Breakthrough Pain","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-02-02","conditions":"Advanced Cancers","enrollment":6},{"nctId":"NCT02597478","phase":"PHASE2, PHASE3","title":"Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-01-04","conditions":"Advanced Cancers","enrollment":50},{"nctId":"NCT01315886","phase":"PHASE4","title":"Conversion From Fast Acting Oral Opioids to Abstral®","status":"TERMINATED","sponsor":"Orexo AB","startDate":"2011-02-21","conditions":"Pain","enrollment":8},{"nctId":"NCT00538850","phase":"PHASE3","title":"Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain","status":"COMPLETED","sponsor":"INSYS Therapeutics Inc","startDate":"2007-10","conditions":"Cancer","enrollment":130},{"nctId":"NCT00538863","phase":"PHASE3","title":"Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain","status":"COMPLETED","sponsor":"INSYS Therapeutics Inc","startDate":"2007-12","conditions":"Cancer, Pain","enrollment":319},{"nctId":"NCT00956254","phase":"PHASE3","title":"Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis","status":"COMPLETED","sponsor":"INSYS Therapeutics Inc","startDate":"2009-10","conditions":"Mucositis, Pain, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1201159"},"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Abstral"],"phase":"marketed","status":"active","brandName":"SL fentanyl","genericName":"SL fentanyl","companyName":"Orexo AB","companyId":"orexo-ab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T04:04:17.657872+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}